Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Chemomab Therapeutics (Nasdaq: CMMB) announced a webinar featuring Dr. Dinesh Khanna, an expert in systemic sclerosis (SSc), on November 3, 2021. The discussion will cover the treatment landscape and clinical utility of CM-101, a monoclonal antibody targeting CCL24. CM-101 is currently being evaluated in Phase 2 trials for various fibrotic conditions, including SSc. As SSc lacks approved disease-modifying treatments, Chemomab aims to address this unmet medical need with its innovative therapies.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced a collaboration with Leeds University to study CCL24's role in vascular damage related to systemic sclerosis (SSc), a severe autoimmune condition. Led by Professor Francesco Del Galdo, this partnership aims to deepen the understanding of CCL24's contribution to SSc pathology. Chemomab plans to assess its CCL24-neutralizing monoclonal antibody, CM-101, in a Phase 2 trial in SSc patients starting early next year, building on existing mechanistic data.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has appointed Dale R. Pfost, PhD, as its new Chief Executive Officer. He will replace co-founder Adi Mor, who will continue as Chief Scientific Officer. Dr. Pfost brings over 30 years of experience in the biotech industry, having successfully led six companies and overseen several public offerings. His appointment reflects a strategic expansion of the senior management team as Chemomab progresses with two ongoing Phase 2 studies and prepares for a third trial. Shareholder approval for his role is expected in Q4 2021.
Chemomab Therapeutics, Ltd (Nasdaq: CMMB), a clinical-stage biotech firm, will attend several investor conferences in September 2021. Key events include the Citi 16th Annual BioPharma Virtual Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, and the Oppenheimer Fall Healthcare Summit on September 22. The company's lead product, CM-101, a monoclonal antibody targeting fibrosis, is currently in Phase 2 trials for primary sclerosing cholangitis and systemic sclerosis. Further information can be found on their website.
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotech firm, reported its financial and operational results for Q2 2021. As of June 30, 2021, the company had $67 million in cash, sufficient to fund operations into mid-2023. The company is advancing three Phase 2 trials for its lead product, CM-101, targeting fibrosis-related diseases. The ongoing SPRING and SPLASH trials are set to yield data in 2022. Despite rising R&D and administrative expenses totaling $2.8 million, Chemomab remains optimistic about its pipeline and collaborations, particularly with AGC Biologics.
Chemomab Therapeutics, Ltd. (NASDAQ: CMMB) has expanded its partnership with AGC Biologics for the manufacturing of CM-101, a Phase II investigational drug targeting fibrosis-related diseases like Primary Sclerosing Cholangitis and Systemic Sclerosis. The agreement aims to optimize and upscale the manufacturing process for upcoming pivotal studies, with clinical trial materials produced in Copenhagen. CM-101 has shown promise in clinical trials, and the collaboration is expected to enhance manufacturing capabilities ahead of Phase 3 trials.
Chemomab Therapeutics (Nasdaq: CMMB) has announced a poster presentation at the International Liver Congress 2021 from June 23-26, 2021. Dr. Arnon Aharon will present findings related to the role of CCL24 in bile duct fibrosis in primary sclerosing cholangitis (PSC). This presentation, titled The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis, highlights CCL24's significance in fibrosis-related diseases. Full poster access will be available on Chemomab's website post-event.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) reported positive financial and operational results for Q1 2021, with a cash position of $58.2 million following a $45 million private placement. Key highlights include positive Phase Ib data for CM-101 in nonalcoholic fatty liver disease (NAFLD) and the initiation of Phase IIa trials for both primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH). The company plans to start an additional Phase II trial for Systemic Sclerosis (SSc) by year-end 2021. Net loss remained stable at $1.7 million for the quarter.
Chemomab Therapeutics Ltd (Nasdaq: CMMB) announced its CEO, Dr. Adi Mor, will present a corporate update at the Oppenheimer Virtual Rare and Orphan Disease Summit on May 21, 2021.
The event aims to share insights on Chemomab's innovative therapeutics targeting fibrosis-related diseases, particularly its monoclonal antibody CM-101, which is in clinical development for orphan diseases like Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc).
The presentation will be available online for 30 days following the event.
Chemomab Therapeutics (Nasdaq: CMMB) has started enrollment for its Phase 2a study of CM-101 aimed at treating Non-Alcoholic Steatohepatitis (NASH). CM-101, a humanized monoclonal antibody, targets CCL24 to mitigate inflammation and fibrosis. The randomized, double-blind trial will involve 40 patients and aims to evaluate CM-101's safety and anti-fibrotic effects, with results expected in the first half of 2022. This study is part of Chemomab’s broader clinical strategy, which includes ongoing trials for other fibrosis-related conditions.
FAQ
What is the current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is the market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is Chemomab Therapeutics Ltd.?
What is CM-101?
What diseases is CM-101 being tested for?
Has CM-101 received any special designations from regulatory authorities?
When are the results from the Phase 2 PSC trial expected?
What recent achievements has Chemomab announced?
What makes CM-101 unique?
What is the significance of the new patents granted to Chemomab?
Where has Chemomab presented its research?
How does CM-101 work?
